Kiniksa Pharmaceuticals International, plc $KNSA Shares Acquired by Fox Run Management L.L.C.

Fox Run Management L.L.C. raised its holdings in shares of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) by 105.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 27,804 shares of the company’s stock after acquiring an additional 14,241 shares during the period. Fox Run Management L.L.C.’s holdings in Kiniksa Pharmaceuticals International were worth $1,147,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in the company. Rubric Capital Management LP increased its holdings in shares of Kiniksa Pharmaceuticals International by 2.3% during the 3rd quarter. Rubric Capital Management LP now owns 4,000,000 shares of the company’s stock valued at $155,320,000 after purchasing an additional 90,194 shares in the last quarter. Vanguard Group Inc. increased its holdings in shares of Kiniksa Pharmaceuticals International by 1.6% during the 4th quarter. Vanguard Group Inc. now owns 3,112,937 shares of the company’s stock valued at $128,409,000 after purchasing an additional 49,802 shares in the last quarter. Arrowstreet Capital Limited Partnership increased its holdings in shares of Kiniksa Pharmaceuticals International by 45.3% during the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 1,068,263 shares of the company’s stock valued at $41,481,000 after purchasing an additional 332,846 shares in the last quarter. Qube Research & Technologies Ltd increased its holdings in shares of Kiniksa Pharmaceuticals International by 277.8% during the 2nd quarter. Qube Research & Technologies Ltd now owns 888,364 shares of the company’s stock valued at $24,581,000 after purchasing an additional 653,236 shares in the last quarter. Finally, Millennium Management LLC increased its holdings in shares of Kiniksa Pharmaceuticals International by 8.7% during the 1st quarter. Millennium Management LLC now owns 847,124 shares of the company’s stock valued at $18,815,000 after purchasing an additional 67,452 shares in the last quarter. 53.95% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, Director Barry D. Quart sold 13,099 shares of the business’s stock in a transaction on Tuesday, April 28th. The shares were sold at an average price of $50.10, for a total value of $656,259.90. Following the completion of the sale, the director owned 12,546 shares of the company’s stock, valued at approximately $628,554.60. The trade was a 51.08% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Sanj K. Patel sold 48,565 shares of the business’s stock in a transaction on Friday, May 1st. The stock was sold at an average price of $54.02, for a total transaction of $2,623,481.30. Following the completion of the sale, the chief executive officer directly owned 48,565 shares of the company’s stock, valued at approximately $2,623,481.30. The trade was a 50.00% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 653,301 shares of company stock worth $34,046,073 in the last 90 days. 51.98% of the stock is owned by insiders.

Analysts Set New Price Targets

KNSA has been the subject of several recent research reports. Weiss Ratings raised shares of Kiniksa Pharmaceuticals International from a “hold (c+)” rating to a “buy (b-)” rating in a report on Monday. Canaccord Genuity Group lifted their target price on shares of Kiniksa Pharmaceuticals International from $62.00 to $64.00 and gave the company a “buy” rating in a report on Wednesday, April 29th. Wedbush lifted their target price on shares of Kiniksa Pharmaceuticals International from $58.00 to $59.00 and gave the company an “outperform” rating in a report on Wednesday, April 29th. Citigroup lifted their target price on shares of Kiniksa Pharmaceuticals International from $50.00 to $60.00 and gave the company a “buy” rating in a report on Wednesday, April 29th. Finally, Wall Street Zen raised shares of Kiniksa Pharmaceuticals International from a “hold” rating to a “strong-buy” rating in a report on Monday, May 4th. Eight equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat, Kiniksa Pharmaceuticals International presently has an average rating of “Moderate Buy” and a consensus target price of $60.86.

Kiniksa Pharmaceuticals International Stock Performance

Shares of NASDAQ KNSA opened at $48.70 on Wednesday. The firm has a market cap of $3.75 billion, a PE ratio of 54.11 and a beta of 0.12. The firm has a fifty day moving average of $50.29 and a 200 day moving average of $45.77. Kiniksa Pharmaceuticals International, plc has a one year low of $26.27 and a one year high of $59.87.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last issued its quarterly earnings results on Tuesday, April 28th. The company reported $0.27 EPS for the quarter, topping the consensus estimate of $0.18 by $0.09. The company had revenue of $214.27 million during the quarter, compared to analyst estimates of $206.11 million. Kiniksa Pharmaceuticals International had a net margin of 9.69% and a return on equity of 13.26%. The firm’s revenue was up 55.5% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.11 EPS. On average, equities analysts predict that Kiniksa Pharmaceuticals International, plc will post 1.24 EPS for the current fiscal year.

Kiniksa Pharmaceuticals International Profile

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.